自体荧光-拉曼显微光谱在基底细胞癌Mohs手术中评估手术切缘的诊断准确性
本研究纳入130例接受Mohs显微描记手术的基底细胞癌患者,用自体荧光-拉曼显微光谱在新鲜切除组织上检测残留肿瘤,以组织学为参考标准。该技术平均覆盖91%标本表面,检测阳性切缘灵敏度67%(95%CI 49-82)、阴性切缘特异度73%(95%CI 63-82),低于Mohs外科医生术中诊断的86%和89%。
要点
- AF-Raman可在30分钟内提供手术切缘的定量诊断图,无需固定、染色或切片。
- AF-Raman检测BCC阳性切缘灵敏度67%,特异度73%,低于Mohs医生术中判断。
- 假阴性主要因血液遮挡或组织与卡匣窗口接触不良导致无有效拉曼信号。
核心结论
- AF-Raman仪器有潜力在BCC手术中提供术中切缘的显微评估,但需改进组织处理以确保标本完全覆盖。
研究设计与样本
- 研究纳入130例在Nottingham大学医院NHS信托接受Mohs手术的患者皮肤层,于2022年9月至2023年7月用AF-Raman仪器在新鲜切除后立即测量。
- 以三位皮肤病理学家术后共识-derived参考为标准,比较AF-Raman结果与Mohs外科医生术中评估,计算灵敏度、特异度及预测值。
- 研究注册于ClinicalTrials.gov(NCT03482622)。
主要发现
- 130层中125层成功完成AF-Raman分析,平均覆盖91%标本表面积,眼睑最低87%,前额最高94%。
- AF-Raman在36例BCC阳性中识别24例阳性切缘(67%灵敏度,95%CI 49-82),在89例BCC阴性中识别65例阴性切缘(73%特异度,95%CI 63-82)。
- 12例假阴性中仅1例由AF-Raman算法误分类导致,其余11例因血液遮挡或组织与卡匣窗口接触不良无有效拉曼信号。
- Mohs外科医生术中诊断在36例BCC阳性中识别31例阳性切缘(86%灵敏度,95%CI 70-95),在89例BCC阴性中识别79例阴性切缘(89%特异度,95%CI 81-95)。
临床怎么用
- AF-Raman可作为术中切缘评估的辅助工具,但当前灵敏度与特异度低于Mohs外科医生判断,不能替代金标准组织学。
- 未来改进组织处理以确保标本完全覆盖后,该技术可能用于指导Mohs手术或帮助无Mohs手术条件的中心。
局限性
- 130层中5层未能成功完成AF-Raman分析。
- 假阴性主要源于血液遮挡或组织与卡匣窗口接触不良等技术因素而非算法误分类。
- 需进一步改进组织处理以保证手术标本的完全覆盖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autofluorescence (AF)-Raman microspectroscopy is a technology that can detect residual basal cell carcinoma (BCC) on the resection margin of fresh, surgically excised tissue specimens. The technology does not require tissue fixation, staining, labelling or sectioning, and provides quantitative diagnosis maps of the surgical margins in 30 min. OBJECTIVES: To determine the accuracy of the AF-Raman instrument in detecting incomplete BCC excisions during Mohs micrographic surgery (MMS), using histology as the reference standard. METHODS: Skin layers from 130 patients undergoing MMS at the Nottingham University Hospitals NHS Trust (September 2022-July 2023) were investigated with the AF-Raman instrument. The layers were measured when fresh, immediately after excision. The AF-Raman results and the intraoperative assessment by Mohs surgeons were compared with a postoperative consensus-derived reference produced by three dermatopathologists. The sensitivity, specificity, and positive and negative predictive values were calculated. The study was registered with ClinicalTrials.gov (NCT03482622). RESULTS: AF-Raman analysis was successfully completed for 125 of 130 layers and, on average, covered 91% of the specimen surface area, with the lowest surface area covered being 87% for the eyelid and the highest being 94% for forehead specimens. The AF-Raman instrument identified positive margins in 24 of 36 BCC-positive cases [67% sensitivity, 95% confidence interval (CI) 49-82] and negative margins in 65 of 89 BCC-negative cases (73% specificity, 95% CI 63-82). Only one of 12 false-negative cases was caused by misclassification by the AF-Raman algorithm. The other 11 false-negatives cases were a result of no valid Raman signal being recorded at the location of the residual BCC due to either occlusion by blood or poor contact between tissue and the cassette window. The intraoperative diagnosis by Mohs surgeons identified positive margins in 31 of 36 BCC-positive cases (86% sensitivity, 95% CI 70-95) and negative margins in 79 of 89 BCC-negative cases (89% specificity, 95% CI 81-95). CONCLUSIONS: The AF-Raman instrument has the potential to provide intraoperative microscopic assessment of surgical margins in BCC surgery. Further improvements are required for tissue processing, to ensure complete coverage of the surgical specimens. Basal cell carcinoma (BCC) is one of the most common human cancers, occurring mostly on the face and neck. Most BCCs are treated by cutting them out under local anaesthetic. This is routinely done in a hospital by a dermatologist or plastic surgeon. Surgery aims to remove all the cancer leaving the smallest scar possible, but it is often difficult to know how much normal skin to remove. Results from the laboratory often take 1 to 2 weeks to show if the cancer is clear. A technique called ‘Mohs’ (micrographic surgery) is recommended for these ‘high-risk’ BCCs. Mohs surgery removes thin layers of skin and investigates them under a microscope while the patient is still in the hospital. This is repeated until all the layers are clear of cancer. Because of the patchy availability of Mohs surgery, many patients with high-risk BCCs are treated by traditional methods that may not be as good as Mohs. We have developed an instrument that scans layers of skin and can quickly detect BCC. The instrument allows surgeons to check each removed skin layer for cancer cells to decide if more layers need to be removed. In this study, the instrument was tested on skin tissue layers from 130 patients who had Mohs surgery at the Nottingham Treatment Centre. The results showed that the instrument can measure skin layers in approximately 30 minutes and identify BCC with a similar accuracy to a Mohs surgeon, but only when the skin layers are prepared properly. With future improvements, the technology might be used to guide Mohs surgery or help surgeons in centres that do not have access to Mohs surgery.
引用
- Boitor RA, Varma S, Sharma A, et al. Diagnostic accuracy of autofluorescence-Raman microspectroscopy for surgical margin assessment during Mohs micrographic surgery of basal cell carcinoma. Br J Dermatol. 2024. PMID: 38736216. doi:10.1093/bjd/ljae196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。